TELA Bio (NASDAQ:TELA) Coverage Initiated by Analysts at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of TELA Bio (NASDAQ:TELA) in a report released on Tuesday morning, The Fly reports. The firm issued a buy rating and a $23.00 target price on the stock.

A number of other equities research analysts also recently weighed in on the company. Canaccord Genuity started coverage on TELA Bio in a research report on Tuesday. They set a buy rating and a $19.00 price target on the stock. JMP Securities assumed coverage on TELA Bio in a research note on Tuesday. They set an outperform rating and a $22.00 price target for the company. Finally, Piper Jaffray Companies assumed coverage on TELA Bio in a report on Tuesday. They issued an overweight rating and a $17.00 price objective for the company.

Shares of NASDAQ:TELA opened at $12.96 on Tuesday. TELA Bio has a 52-week low of $10.78 and a 52-week high of $15.05.

In other TELA Bio news, major shareholder Orbimed Advisors Llc bought 384,615 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were bought at an average price of $12.09 per share, for a total transaction of $4,649,995.35. Also, Director Matt Zuga purchased 86,121 shares of the stock in a transaction on Friday, November 8th. The stock was acquired at an average cost of $12.09 per share, with a total value of $1,041,202.89.

About TELA Bio

TELA Bio, Inc, a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. It offers reinforced tissue matrix products for a variety of reconstruction procedures, including hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.

Further Reading: What is a Fiduciary?

The Fly

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.